How Can We Help You?

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Uterine Fibroids

Select Clinical Trial

ObsEva 16-OBE2109-008 – Phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

  •  Premenopausal women over 18, with menstrual cycles 21-40 days 

16-OBE2109-008 -A Phase 3, multicentre, randomized, double-blind, placebocontrolled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with addback therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

  • Premenopausal woman, Menstrual cycles ≥ 21 days and ≤ 40 days, presence of uterine fibroids, heavy menstrual blood loss
Specialties
Clara McLean House
Make a Donation
News & Events